LKT Labs

Biochemicals for Life Science Research

Dabrafenib Mesylate

Product ID D0005
Cas No. 1195768-06-9
Purity ≥98%
Product Unit SizeCostQuantityStock
5 mg $62.50 In stock
25 mg $225.10 In stock
100 mg $562.60 In stock
Bulk Quote
Browse Wishlist

Quicklinks

Description

Dabrafenib is a reversible kinase inhibitor with anticancer chemotherapeutic activity. This compound is selective primarily for mutant (V600E) B-Raf, but has also inhibited tumor growth in cells expressing other B-Raf mutants (V600K, V600D) and WT B-Raf. Dabrafenib is partially active against c-Raf as well. Dabrafenib is an ATP-competitive inhibitor that has been approved for clinical use in the treatment of unresectable or metastatic melanomas; it is also being examined for treatment of brain metastases and other cancers. This compound has a very high oral bioavailability.

Product Info

Cas No.

1195768-06-9
Purity

≥98%
Formula

C23H20F3N5O2S2・CH3SO3H
Formula Wt.

615.67
Chemical Name

N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1, 3-thiazol-4-yl]-2-fluorophenyl]-2, 6-difluorobenzenesulfonamide;methanesulfonic acid
IUPAC Name

N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1, 3-thiazol-4-yl]-2-fluorophenyl]-2, 6-difluorobenzenesulfonamide;methanesulfonic acid
Solubility

soluble in DMSO
Appearance

White Crystal Powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

D0005 MSDS PDF
Info Sheet

D0005 Info Sheet PDF
Brochures

Ras-Raf-MEK-ERK Pathway Booklet

References

Ballantyne AD, Garnock-Jones KP. Dabrafenib: First Global Approval. Drugs. 2013 Jul 24. [Epub ahead of print] PMID: 23881668.

Huang T, Karsy M, Zhuge J, et al. B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol. 2013 Apr 25;6:30. PMID: 23617957.

Klinac D, Gray ES, Millward M, et al. Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol. 2013;3:54. PMID: 23515890.

Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012 Jul 28;380(9839):358-65. PMID: 22735384.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.